Literature DB >> 21252988

Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.

B Paiva1, M Pérez-Andrés, M-B Vídriales, J Almeida, N de las Heras, M-V Mateos, L López-Corral, N C Gutiérrez, J Blanco, A Oriol, M T Hernández, F de Arriba, A G de Coca, M-J Terol, J de la Rubia, Y González, A Martín, A Sureda, M Schmidt-Hieber, A Schmitz, H E Johnsen, J-J Lahuerta, J Bladé, J F San-Miguel, A Orfao.   

Abstract

Disappearance of normal bone marrow (BM) plasma cells (PC) predicts malignant transformation of monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) into symptomatic multiple myeloma (MM). The homing, behavior and survival of normal PC, but also CD34(+) hematopoietic stem cells (HSC), B-cell precursors, and clonal PC largely depends on their interaction with stromal cell-derived factor-1 (SDF-1) expressing, potentially overlapping BM stromal cell niches. Here, we investigate the distribution, phenotypic characteristics and competitive migration capacity of these cell populations in patients with MGUS, SMM and MM vs healthy adults (HA) aged >60 years. Our results show that BM and peripheral blood (PB) clonal PC progressively increase from MGUS to MM, the latter showing a slightly more immature immunophenotype. Of note, such increased number of clonal PC is associated with progressive depletion of normal PC, B-cell precursors and CD34(+) HSC in the BM, also with a parallel increase in PB. In an ex vivo model, normal PC, B-cell precursors and CD34(+) HSC from MGUS and SMM, but not MM patients, were able to abrogate the migration of clonal PC into serial concentrations of SDF-1. Overall, our results show that progressive competition and replacement of normal BM cells by clonal PC is associated with more advanced disease in patients with MGUS, SMM and MM.

Entities:  

Mesh:

Year:  2011        PMID: 21252988     DOI: 10.1038/leu.2010.320

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  31 in total

1.  Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.

Authors:  Roberto J Pessoa de Magalhães; María-Belén Vidriales; Bruno Paiva; Carlos Fernandez-Gimenez; Ramón García-Sanz; Maria-Victoria Mateos; Norma C Gutierrez; Quentin Lecrevisse; Juan F Blanco; Jose Hernández; Natalia de las Heras; Joaquin Martinez-Lopez; Monica Roig; Elaine Sobral Costa; Enrique M Ocio; Martin Perez-Andres; Angelo Maiolino; Marcio Nucci; Javier De La Rubia; Juan-Jose Lahuerta; Jesús F San-Miguel; Alberto Orfao
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

2.  CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype.

Authors:  Teresa Paíno; Enrique M Ocio; Bruno Paiva; Laura San-Segundo; Mercedes Garayoa; Norma C Gutiérrez; M Eugenia Sarasquete; Atanasio Pandiella; Alberto Orfao; Jesús F San Miguel
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

3.  Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes.

Authors:  Syed J Mehdi; Sarah K Johnson; Joshua Epstein; Maurizio Zangari; Pingping Qu; Antje Hoering; Frits van Rhee; Carolina Schinke; Sharmilan Thanendrarajan; Bart Barlogie; Faith E Davies; Gareth J Morgan; Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2018-11-08       Impact factor: 6.998

4.  Reply to “Response to “CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype”. Haematologica 2012;97(7):1110-1114.

Authors:  Teresa Paíno; Bruno Paiva; Jesús San Miguel
Journal:  Haematologica       Date:  2013-01       Impact factor: 9.941

Review 5.  The myeloma stem cell concept, revisited: from phenomenology to operational terms.

Authors:  Hans Erik Johnsen; Martin Bøgsted; Alexander Schmitz; Julie Støve Bødker; Tarec Christoffer El-Galaly; Preben Johansen; Peter Valent; Niklas Zojer; Els Van Valckenborgh; Karin Vanderkerken; Mark van Duin; Pieter Sonneveld; Martin Perez-Andres; Alberto Orfao; Karen Dybkær
Journal:  Haematologica       Date:  2016-11-10       Impact factor: 9.941

6.  Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination.

Authors:  Juan-Jose Garcés; Michal Simicek; Marco Vicari; Lucie Brozova; Leire Burgos; Renata Bezdekova; Diego Alignani; Maria-Jose Calasanz; Katerina Growkova; Ibai Goicoechea; Xabier Agirre; Ludek Pour; Felipe Prosper; Rafael Rios; Joaquin Martinez-Lopez; Pamela Millacoy; Luis Palomera; Rafael Del Orbe; Albert Perez-Montaña; Sonia Garate; Laura Blanco; Marta Lasa; Patricia Maiso; Juan Flores-Montero; Luzalba Sanoja-Flores; Zuzana Chyra; Alexander Vdovin; Tereza Sevcikova; Tomas Jelinek; Cirino Botta; Halima El Omri; Jonathan Keats; Alberto Orfao; Roman Hajek; Jesus F San-Miguel; Bruno Paiva
Journal:  Leukemia       Date:  2019-10-08       Impact factor: 11.528

7.  The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma.

Authors:  Toshi Ghosh; Wilson I Gonsalves; Dragan Jevremovic; Angela Dispenzieri; David Dingli; Michael M Timm; William G Morice; Prashant Kapoor; Taxiarchis V Kourelis; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Nelson Leung; Ronald S Go; Yi Lin; Stephen J Russell; John A Lust; Steven R Zeldenrust; Rahma Warsame; Yi L Hwa; Robert A Kyle; Morie A Gertz; S Vincent Rajkumar; Shaji K Kumar
Journal:  Am J Hematol       Date:  2017-07-19       Impact factor: 10.047

Review 8.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

9.  Detection of monoclonal IGH rearrangements in circulating cells from healthy first-degree relatives of patients with multiple myeloma.

Authors:  Herbert García-Castillo; Evelia Leal-Ugarte; Pablo César Ortiz Lazareno; Esperanza Barrera-Chairez; Víctor Hugo Rosales-García; Patricio Barros-Núñez
Journal:  Med Oncol       Date:  2014-03-01       Impact factor: 3.064

10.  Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Leandro S Thiago; Martin Perez-Andres; Ana Balanzategui; Maria E Sarasquete; Bruno Paiva; Maria Jara-Acevedo; Paloma Barcena; Maria Luz Sanchez; Julia Almeida; Marcos González; Jesus F San Miguel; Ramón Garcia-Sanz; Alberto Orfao
Journal:  Haematologica       Date:  2013-07-19       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.